Drug intelligence / Profile preview

paracetamol + caffeine + chlorpheniramine

Development stage
Unknown
Lead developer
Jilin Oriental Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

This combination drug is a multi-ingredient pharmaceutical product used for the symptomatic relief of the common cold and influenza. It consists of three primary active small molecules: **paracetamol** (acetaminophen), **caffeine**, and **chlorpheniramine**. Paracetamol serves as an analgesic and antipyretic by inhibiting prostaglandin synthesis, primarily within the central nervous system. Caffeine is included as a central nervous system stimulant to enhance the analgesic efficacy of paracetamol and to mitigate the sedative effects often associated with antihistamines. Chlorpheniramine is a first-generation H1-receptor antagonist that effectively reduces allergic-type symptoms such as rhinorrhea, sneezing, and watery eyes. Developed and manufactured by Jilin Province Oriental Pharmaceutical, this oral formulation is indicated for treating fever, headache, sore throat, and nasal congestion associated with upper respiratory tract infections.

Brand names
Amkahuangmin Capsules
Other names
acetaminophen + caffeine + chlorpheniramineparacetamol + caffeine + chlorpheniramine maleateacetaminophen + caffeine + chlorpheniramine maleateAmkahuangAnfenkahuang
02

Targets

ADOR (Adenosine receptors)COXHRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on paracetamol + caffeine + chlorpheniramine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on paracetamol + caffeine + chlorpheniramine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call